Purchase to lift Sandoz in respiratory RX market.
HOLZKIRCHEN, Germany -- Sandoz has signed an agreement to acquire Oriel Therapeutics, a privately held American pharmaceutical company. The deal gives Sandoz exclusive rights to a portfolio of generic drug candidates and related technologies that target medicines in the inhalable respiratory drag market. Terms of the transaction were not disclosed.
Oriel focuses on developing respiratory products with known pathways as generic altematives to patented drugs for asthma and chronic obstructive pulmonary disease. The acquisition provides Sandoz with three promising development projects targeting leading medicines in this field.
Regulatory approvals of these medicines (if achieved) would enable Sandoz to increase access to affordable therapeutic alternatives for these increasingly prevalent diseases.
The acquisition of Oriel, which will be integrated as a separate development unit within Sandoz, also offers Sandoz access to its novel FreePath drug delivery technology, which Sandoz notes has the potential to address some of the hurdles facing regulatory approval of generic inhaled medicines in the U.S.
Oriel has also developed the proprietary Solis disposable dry powder inhaler, which is based on the FreePath delivery technology.
Sandoz says the acquisition will enable it to leverage both its established range of in-market products and its extensive in-house expertise.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||RX RETAIL PHARMACY: Generic Drugs|
|Publication:||Chain Drug Review|
|Article Type:||Brief article|
|Date:||May 24, 2010|
|Previous Article:||Host of new generics ready for market.|
|Next Article:||Bill in Missouri is under fire.|